Cargando…

Recombinant FXIII (rFXIII-A (2) ) Prophylaxis Prevents Bleeding and Allows for Surgery in Patients with Congenital FXIII A-Subunit Deficiency

Recombinant factor XIII-A (2) (rFXIII-A (2) ) was developed for prophylaxis and treatment of bleeds in patients with congenital FXIII A-subunit deficiency. mentor™2 (NCT00978380), a multinational, open-label, single-arm, multiple-dosing extension to the pivotal mentor™1 trial, assessed long-term saf...

Descripción completa

Detalles Bibliográficos
Autores principales:	Carcao, Manuel, Altisent, Carmen, Castaman, Giancarlo, Fukutake, Katsuyuki, Kerlin, Bryce A., Kessler, Craig, Lassila, Riitta, Nugent, Diane, Oldenburg, Johannes, Garly, May-Lill, Rosholm, Anders, Inbal, Aida
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Schattauer GmbH 2018
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6260112/ https://www.ncbi.nlm.nih.gov/pubmed/29448295 http://dx.doi.org/10.1055/s-0038-1624581

Ejemplares similares

Successful treatment of intractable pseudomeningocele with FXIII deficiency by surgery and FXIII replacement therapy: A case report
por: Takamatsu, Nobutoshi, et al.
Publicado: (2022)

Common FXIII and Fibrinogen Polymorphisms in Abdominal Aortic Aneurysms
por: Macrae, Fraser L., et al.
Publicado: (2014)

Cellular FXIII in Human Macrophage-Derived Foam Cells
por: Somodi, Laura, et al.
Publicado: (2023)

Does FXIII Deficiency Impair Wound Healing after Myocardial Infarction?
por: Nahrendorf, Matthias, et al.
Publicado: (2006)

The Effect of Activated FXIII, a Transglutaminase, on Vascular Smooth Muscle Cells
por: Bogáti, Réka, et al.
Publicado: (2022)

PB2652: EVALUATION OF 6 CASES WITH FXIII DEFICIENCY: SINGLE CENTRE EXPERIENCE
por: Sahin, Fahri, et al.
Publicado: (2023)

Disruption of Structural Disulfides of Coagulation FXIII-B Subunit; Functional Implications for a Rare Bleeding Disorder
por: Singh, Sneha, et al.
Publicado: (2019)

Nonclinical analysis of the safety, pharmacodynamics, and pharmacokinetics of plasma‐derived human FXIII concentrate in animals
por: Beyerle, Andrea, et al.
Publicado: (2016)

Low FXIII activity levels in intensive care unit hospitalized COVID-19 patients
por: Lichter, Yael, et al.
Publicado: (2021)

The association of alcohol with circulating total fibrinogen and plasma clot density is mediated by fibrinogen and FXIII genotypes
por: Rautenbach, Petro Hannie, et al.
Publicado: (2020)

The perioperative management of cesarean section in a patient with FXIII deficiency and placenta previa: a case report
por: Ueda, Kei, et al.
Publicado: (2022)

The Need for Red Cell Support During Non-Cardiac Surgery Is Associated to Pre-Transfusion Levels of FXIII and the Platelet Count
por: Listyo, Silke, et al.
Publicado: (2020)

Identification of Potential Novel Interacting Partners for Coagulation Factor XIII B (FXIII-B) Subunit, a Protein Associated with a Rare Bleeding Disorder
por: Singh, Sneha, et al.
Publicado: (2019)

Lack of Associations Between PAI-1 and FXIII Polymorphisms and Arterial Ischemic Stroke in Children: A Systematic Review and Meta-Analysis
por: Sarecka-Hujar, Beata, et al.
Publicado: (2019)

Normalization of blood clotting characteristics using prothrombin complex concentrate, fibrinogen and FXIII in an albumin based fluid: experimental studies in thromboelastometry
por: Koller, Tobias, et al.
Publicado: (2021)

Recurrent Miscarriage and Implantation Failure of Unknown Cause Studied by a Panel of Thrombophilia Conditions: Increased Frequency of FXIII Val34Leu Polymorphism
por: Diaz-Nuñez, Maria, et al.
Publicado: (2019)

Phenotype and genotype of FXIII deficiency in two unrelated probands: identification of a novel F13A1 large deletion mediated by complex rearrangement
por: Ma, Siyu, et al.
Publicado: (2019)

Coagulation FXIII-A Protein Expression Defines Three Novel Sub-populations in Pediatric B-Cell Progenitor Acute Lymphoblastic Leukemia Characterized by Distinct Gene Expression Signatures
por: Gyurina, Katalin, et al.
Publicado: (2019)

Safety and effectiveness of recombinant factor XIII‐A(2) in congenital factor XIII deficiency: Real‐world evidence
por: Poulsen, Lone Hvitfeldt, et al.
Publicado: (2022)

The role of FV 1691G>A, FII 20210G>A mutations and MTHFR 677C>T; 1298A>C and 103G>T FXIII gene polymorphisms in pathogenesis of intraventricular hemorrhage in infants born before 32 weeks of gestation
por: Szpecht, Dawid, et al.
Publicado: (2017)

Real-World Use of Albutrepenonacog Alfa, A Recombinant Coagulation Factor IX Albumin Fusion Protein, for Personalized Prophylaxis in Japanese Individuals With Hemophilia B: A Case Series
por: Nagao, Azusa, et al.
Publicado: (2023)

High adherence to prophylaxis regimens in haemophilia B patients receiving rIX‐FP: Evidence from clinical trials and real‐world practice
por: Mancuso, Maria Elisa, et al.
Publicado: (2020)

Decreased Bleeding Rates in Patients with Hemophilia A Switching from Standard-Half-Life FVIII to BAY 94-9027 Prophylaxis
por: Mancuso, Maria Elisa, et al.
Publicado: (2021)

Thrombosis of the Abdominal Veins in Childhood
por: Kumar, Riten, et al.
Publicado: (2017)

The optimal age of measles immunisation in low-income countries: a secondary analysis of the assumptions underlying the current policy
por: Aaby, Peter, et al.
Publicado: (2012)

Long-term efficacy and safety of subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors
por: Shapiro, Amy D., et al.
Publicado: (2022)

Protease‐activated receptors: An illustrated review
por: Han, Xu, et al.
Publicado: (2020)

Identification of deep intronic individual variants in patients with hemophilia A by next‐generation sequencing of the whole factor VIII gene
por: Inaba, Hiroshi, et al.
Publicado: (2017)

Nonacog beta pegol (N9‐GP) in hemophilia B: First report on safety and efficacy in previously untreated and minimally treated patients
por: Chan, Anthony K., et al.
Publicado: (2020)

Recombinant FIX Fc fusion protein activity assessment with the one‐stage clotting assay: A multicenter, assessor‐blinded, prospective study in Japan (J‐Field Study)
por: Fukutake, Katsuyuki, et al.
Publicado: (2019)

Andexanet Alfa Versus Prothrombin Complex Concentrates/Blood Products as Apixaban/Rivaroxaban Reversal Agents: A Survey Among Pediatric Hematologists
por: Rodriguez, Vilmarie, et al.
Publicado: (2022)

Planificación anticipada de la asistencia. Se necesita una revolución educativa
por: Altisent, Rogelio
Publicado: (2013)

La insidiosa enfermedad de los conflictos de interés en medicina
por: Altisent, Rogelio
Publicado: (2019)

Protective efficacy of standard Edmonston-Zagreb measles vaccination in infants aged 4.5 months: interim analysis of a randomised clinical trial
por: Martins, Cesário L, et al.
Publicado: (2008)

Plasma Cytokine Profiling to Predict Steroid Resistance in Pediatric Nephrotic Syndrome
por: Agrawal, Shipra, et al.
Publicado: (2021)

The changing face of immune tolerance induction in haemophilia A with the advent of emicizumab
por: Carcao, Manuel, et al.
Publicado: (2019)

Effect of emicizumab prophylaxis on bone and joint health markers in people with haemophilia A without factor VIII inhibitors in the HAVEN 3 study
por: Kiialainen, Anna, et al.
Publicado: (2022)

Fixed doses of N8‐GP prophylaxis maintain moderate‐to‐mild factor VIII levels in the majority of patients with severe hemophilia A
por: Chowdary, Pratima, et al.
Publicado: (2019)

Interaction between neonatal vitamin A supplementation and timing of measles vaccination: A retrospective analysis of three randomized trials from Guinea-Bissau()
por: Benn, Christine S., et al.
Publicado: (2014)

Defining the HIV pre-exposure prophylaxis care continuum
por: Nunn, Amy S., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_fjiumra6g8jti7btp53ajbqpsf